Checkmate Pharmaceuticals
1 Broadway, 14th floor
Cambridge
Massachusetts
02142
United States
Website: http://checkmatepharma.com/
About Checkmate Pharmaceuticals
39 articles with Checkmate Pharmaceuticals
-
Checkmate Pharmaceuticals Secures $85 Million in Series C Financing
6/10/2020
Checkmate Pharmaceuticals (Checkmate), a clinical stage biotechnology company focused on improving patients’ lives with its novel approach to cancer immunotherapy, announced that it has completed an $85 million Series C financing. Checkmate plans to use the proceeds from t
-
Genialis Advances Precision Medicine Solutions for Diseases of Unmet Need
1/8/2020
Company builds partnerships, adds to the scientific and technology teams to drive new solutions for patients worldwide
-
Checkmate Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/8/2020
Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat cancer, today announced that it will make a presentation at the 38th Annual J.P. Morgan Healthcare Conference.
-
Checkmate Pharmaceuticals Presents Positive Clinical Data with CMP-001 at The 34th Annual Meeting of The Society for Immunotherapy of Cancer (SITC)
11/5/2019
Checkmate Pharmaceuticals Inc. (Checkmate), a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat cancer, today announced the presentation of new data from two ongoing clinical trials evaluating CMP-001, Checkmate’s Toll-like receptor 9 (TLR9) agonist, in combination with the anti-PD-1 therapies pembrolizumab (KEYTRUDA®) or nivolumab (OPDIVO®), in patients with melanoma.
-
Checkmate Pharmaceuticals Announces Data Presentations for Lead Program at The 34th Annual Meeting of The Society for Immunotherapy of Cancer
11/1/2019
Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat cancer, today announced two oral presentations at The 34th Annual Meeting of The Society for Immunotherapy of Cancer (SITC).
-
Checkmate Pharmaceuticals Announces Appointment of Kleem Chaudhary as Chief Business Officer
10/31/2019
Dr. Chaudhary has over 16 years of experience within the biotech and large pharmaceutical industry with broad experience in strategic business development and drug discovery.
-
Checkmate Pharmaceuticals Announces Additions to Management Team
10/15/2019
Experienced Industry Executives to Lead Clinical Research and Regulatory Affairs with the Appointments of James Wooldridge, MD, as Chief Medical Officer and Steven Hamburger, PhD, as Vice President of Regulatory Affairs
-
Checkmate Pharmaceuticals Announces Dosing of First Patient in a Phase 1b/2 Study in Squamous Cell Carcinoma of the Head and Neck with Lead Investigational Candidate CMP-001
10/1/2019
CMP-001, a TLR9 Agonist, to be Evaluated in Combination with BAVENCIO®; with or without Utomilumab, a 4-1BB Agonist, and PF-04518600, an OX40 Agonist
-
What if you could more precisely control CAR-T cells using FDA-approved small molecules to enhance their activity against solid tumors? That’s exactly what Obsidian Therapeutics is aiming to do.
-
Checkmate Pharmaceuticals Announces Appointment of Alan Fuhrman to Board of Directors
7/16/2019
Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat advanced cancer, announced the addition of Alan Fuhrman to its Board of Directors.
-
Checkmate Pharmaceuticals Announces Appointment of Keith T. Flaherty, M.D. to its Board of Directors
4/9/2019
Checkmate Pharmaceuticals Inc. announced the addition of Keith T. Flaherty, M.D. to its Board of Directors.
-
Checkmate Pharmaceuticals Announces CEO Transition and $22 Million Financing
12/12/2018
Checkmate Pharmaceuticals, a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat advanced cancer, has appointed Barry Labinger as President and CEO. Arthur M. Krieg, MD, Checkmate’s founder and current President and CEO, will assume the newly-created role of Chief Scientific Officer.
-
Checkmate Pharmaceuticals Announces Start of Phase 1b Trial of CMP-001 in Combination with Anti-PD-L1 Immunotherapy in Anti-PD-1/PD-L1 Resistant Advanced Non-Small Cell Lung Cancer
4/24/2018
CMP-001 Clinical Studies Expand into Second Tumor Type
-
The following is a roundup of presentations and findings from multiple companies participating in the 2018 American Association for Cancer Research (AACR) in Chicago.
-
Checkmate Notches $27 Million and Taps Ex-FORUM Pharma Exec as COO
6/19/2017
-
Checkmate Appoints David Mauro, M.D., Ph.D., As Chief Medical Officer And Announces Dosing Of First Patient In Immuno-Oncology Phase 1b Trial With CMP-001, A TLR9 Agonist
4/20/2016
-
BioSpace is pleased to present its NextGen Bio “Class of 2016.” This list contains 20 life science companies that launched no earlier than 2013 and are headquartered in the United States.
-
What You Need to Know About Checkmate
12/2/2015
-
Checkmate Comes Out of Stealth Mode With $20 Million and Ex-Sarepta Exec as Its Leader
8/13/2015